Frequently Asked Questions

AlcoChange is a prescription-only, UKCA-marked, Class IIa digital therapeutic designed to support the reduction of alcohol use and the maintenance of abstinence in adults (aged 18 or over) with established alcohol-related liver disease (ARLD). It is manufactured by CyberLiver Limited and is used as an adjunct to standard clinical care, under the supervision of a qualified clinical team.

AlcoChange is indicated for adults aged 18 years or over who have an established diagnosis of alcohol-related liver disease. It must be prescribed by a qualified clinician and is not available for direct purchase. Patients should discuss suitability with their treating clinical team.

AlcoChange is prescribed by a qualified clinician as part of the patient's treatment plan. The clinician registers the patient, who then receives access to the mobile application. The clinical team monitors the patient's progress throughout the 90-day programme using a web-based clinician dashboard.

Over the 90-day treatment course, AlcoChange delivers personalised behavioural change interventions based on the CyberLiver Behaviour Change (CBC) Model. This includes 34 digital behaviour change techniques and over 150 behaviour change notifications, adapted to the patient's responses and engagement patterns. The application collects self-reported data and, where applicable, breathalyser readings, to inform the clinical team's oversight.

The digital breathalyser is an optional companion accessory that connects to the AlcoChange mobile application via Bluetooth. It enables patients to provide objective breath-alcohol readings as part of their self-monitoring. Use of the breathalyser is determined by the prescribing clinician and is not a mandatory component of the programme.

Yes. AlcoChange processes personal and health data in accordance with UK GDPR and the Data Protection Act 2018. Data is encrypted in transit and at rest, and access is restricted to the patient and their authorised clinical team. CyberLiver Limited maintains a comprehensive information security management system. Full details are available in the AlcoChange Privacy Policy.

No. AlcoChange is designed to be used as an adjunct to standard clinical care. It does not replace the patient's clinical team or any element of their existing treatment plan. The supervising clinical team retains full responsibility for the patient's care and uses the clinician dashboard to monitor progress during the programme.

AlcoChange has been evaluated in a peer-reviewed feasibility pilot (Mehta et al., JHEP Reports, 2024), which demonstrated the feasibility of delivering the 90-day programme within routine hepatology care. A larger, NIHR-funded, multi-centre randomised controlled trial (ISRCTN10911773) is currently being conducted across 25 NHS Trusts with 324 patients recruited. Results are expected Q3 to Q4 2026. For more details, visit our Press and Publications page.

For general enquiries, you can reach us at enquiries@alcochange.com or through our Contact page. If you are a patient currently enrolled in the AlcoChange programme, please contact your clinical team in the first instance for any clinical questions or concerns.

The Instructions for Use (IFU) and other regulatory documents are available on our Information Materials page. These documents provide detailed information about the device, its intended use, contraindications and safety information.